Raltegravir

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

HIV Prevention

Conditions

HIV Prevention, HIV Infections

Trial Timeline

Jul 1, 2010 → Jul 1, 2012

NCT ID

NCT01087840

About Raltegravir

Raltegravir is a approved stage product being developed by Merck for HIV Prevention. The current trial status is completed. This product is registered under clinical trial identifier NCT01087840. Target conditions include HIV Prevention, HIV Infections.

What happened to similar drugs?

8 of 20 similar drugs in HIV Prevention were approved

Approved (8) Terminated (0) Active (12)

✅Meningococcal C conjugate vaccineNovartisApproved

✅Boostrix + Placebo (Saline)NovartisApproved

✅Meningococcal C conjugate vaccineNovartisApproved

✅Lenacapavir long-actingGilead SciencesApproved

✅DescovyGilead SciencesApproved

✅13-valent Pneumococcal conjugate vaccinePfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00377065	Pre-clinical	Completed	—	—	HIV Infections
NCT03732625	Approved	UNKNOWN	May 1, 2019	Jan 1, 2021	HIV Infections
NCT03667547	Approved	Completed	Sep 27, 2018	Oct 23, 2018	Human Immunodeficiency Virus (HIV) Infection
NCT03374358	Approved	Completed	Jan 10, 2018	Nov 30, 2019	HIV Seropositivity
NCT02097108	Phase 2	Completed	May 1, 2014	Dec 1, 2015	HIV Infections
NCT01978743	Pre-clinical	Completed	Jan 1, 2014	Jan 1, 2017	HIV
NCT01767701	Phase 2	Completed	Apr 1, 2013	Sep 1, 2014	Relapsing Remitting Multiple Sclerosis
NCT01453933	Approved	UNKNOWN	Jan 1, 2012	Dec 1, 2014	HIV Infection
NCT01620736	Phase 2	Withdrawn	Jan 1, 2012	Dec 1, 2014	Human T-cell Leukemia Virus Type 1 Infection
NCT01453192	Phase 3	Completed	Dec 1, 2011	Nov 1, 2015	HIV-1 Infection
NCT01448486	Approved	Terminated	Oct 1, 2011	Oct 1, 2013	Human Immunodeficiency Virus (HIV)
NCT01327482	Pre-clinical	Completed	Oct 1, 2011	—	HIV
NCT01325051	Phase 1	Completed	Apr 1, 2011	Nov 1, 2011	Healthy Volunteer
NCT01042652	Pre-clinical	UNKNOWN	Feb 1, 2011	Jun 1, 2012	HIV
NCT01164605	Pre-clinical	UNKNOWN	Oct 1, 2010	Jun 1, 2013	HIV Infection
NCT01087840	Approved	Completed	Jul 1, 2010	Jul 1, 2012	HIV Prevention
NCT01027182	Phase 1	Completed	Dec 1, 2009	Mar 1, 2010	Human Immunodeficiency Virus
NCT00939874	Approved	Completed	Oct 1, 2009	Apr 1, 2014	HIV
NCT00807443	Phase 2	Completed	Sep 1, 2009	Dec 1, 2011	HIV-1
NCT00887653	Phase 3	Completed	May 1, 2009	Apr 1, 2014	HIV

Competing Products

20 competing products in HIV Prevention

See all competitors

Product	Company	Stage	Hype Score
mRNA-1944	Moderna	Phase 1	0
Gam-COVID-Vac	Dr. Reddy's Laboratories	Phase 2/3	31
edoxaban + enoxaparin sodium	Daiichi Sankyo	Phase 3	40
Mifepristone	Eli Lilly	Phase 2	35
EXANTA	AstraZeneca	Phase 2	27
Risk of low dose aspirin discontinuation	AstraZeneca	Pre-clinical	26
DAPA/MET XR + DAPA + MET XR	AstraZeneca	Phase 3	40
Esomeprazole + Placebo	AstraZeneca	Phase 3	40
PCV15	Merck	Pre-clinical	18
RotaTeq (V260) + IPV	Merck	Phase 3	40
V501	Merck	Phase 3	40
Zostavax	Merck	Phase 3	40
V920 Consistency Lot A + V920 Consistency Lot B + V920 Consistency Lot C + V920 High-dose Lot + Placebo to V920	Merck	Phase 3	40
Letermovir + Placebo	Merck	Phase 3	40
Meningococcal C conjugate vaccine	Novartis	Approved	43
Enteric-coated mycophenolate sodium	Novartis	Phase 3	40
Meningococcal C conjugate vaccine	Novartis	Approved	43
rMenB+OMV NZ	Novartis	Phase 3	40
Enteric-Coated Mycophenolate Sodium	Novartis	Phase 3	40
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL + Placebo in 1.5ml	Novartis	Phase 3	44